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Prostate cancer can progress from androgen dependence to androgen deprivation
resistance with some unknown mechanisms. The current study aims to explore the
possible role of pituitary tumor transforming gene1 (PTTG1) in castration-resistant
prostate cancer (CRPC). Initially, we found that PTTG1 expression was significantly
increased in androgen-independent prostate cancer cell lines PC3, DU145 and
CRPC specimens compared with that in androgen-dependent prostate cancer cell
line LNCaP and initial prostate cancer specimens. PTTG1 overexpression signifi-
cantly enhanced the cell survival rate, clonality and tumorigenicity in LNCaP cells
upon androgen-deprivation therapy (ADT). While knockdown of PTTG1 expression
significantly elevated the sensitivity of DU145 cells to ADT. The effects of PTTG1
overexpression on LNCaP cells may be ascribed to the induced EMT and increased
CD44+CD24- cancer stem cell population. Furthermore, we detected that PTTG1
expression was regulated by interleukin-6 via activated signal transducer and activa-
tor of transcription 3 (STAT3) directly binding to the region 500 to +1 of PTTG1
promoter in LNCaP cells. In conclusion, our results elucidate that interleukin-6/
STAT3 activation can increase PTTG1 expression and, consequently, promote the
resistance to ADT in CRPC by inducing EMT and increasing the cancer stem cell
population, suggesting that PTTG1 may be a novel therapeutic target for CRPC.
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1 | INTRODUCTION
Prostate cancer (PCa) is the second most common cancer worldwide,
and the 6th leading cause of cancer-related death (258 400 deaths
annually).1 Although the PCa incidence in China was reported to be
ranked 117th among all nations, it has substantially increased since
2010.2 Nowadays, androgen deprivation therapy (ADT) is the main-
stay therapy for advanced prostate cancer in addition to surgery.3
Although ADT is initially effective in suppressing tumor growth and
survival, many prostate cancer patients will undergo recurrence and
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progress on anti-androgen therapy, reaching a lethal stage termed
castration-resistant prostate cancer (CRPC).4 There is an urgent need
to explore the mechanisms of castration resistance, which will pro-
vide better intervention strategies for CRPC patients.
Pituitary tumor transforming 1 (PTTG1) is an oncogene that was
originally cloned from rat pituitary tumor cells.5 PTTG1 overexpres-
sion can interfere with sister chromatid separation during mitosis,
leading to chromosome aneuploidy.6 Therefore, PTTG1 is involved in
the development and progression in many malignancies.7 In our pre-
vious studies, we demonstrated that PTTG1 expression was signifi-
cantly increased in human prostate cancer metastasis tissue,8 and
PTTG1 promoted the proliferation of prostate cancer cells by inhibit-
ing SMAD3.9 Moreover, the PTTG1 mRNA expression was higher in
androgen-independent prostate cancer cell lines PC3 or DU145 than
that in androgen-dependent prostate cancer cell line LNCaP.10 These
results indicate that PTTG1 may play an important role in the devel-
opment of castration resistance in CRPC. However, the exact role
and potential mechanisms underlying the involvement of PTTG1 in
CRPC are poorly clarified.
A series of studies has demonstrated that development and pro-
gression of CRPC are closely related to interleukin-6 (IL-6). IL-6 is
abundantly expressed in androgen-independent prostate cancer cell
lines PC3 or DU145. In contrast, IL-6 expression in androgen-depen-
dent prostate cancer cell line LNCaP is found to be negative.11
However, the gain of IL-6 expression in LNCaP cells through lentivi-
ral transfection can lead these cells to be resistant to ADT.12 In
addition, IL-6 levels in plasma and serum from patients with CRPC
are significantly higher than those from patients with earlier stages
of prostate cancer and healthy individuals.13 Furthermore, it has
been postulated that IL-6 can regulate the expression of androgen-
responsive genes in low androgen conditions and thereby contribute
to the transition from hormone-dependent to CRPC.14 As a novel
downstream target gene of androgen receptor,8 we consider
whether PTTG1 can be regulated by IL-6 and is consequently
involved in the development of castration resistance in CRPC. The
current study aims to verify this hypothesis and further explore the
potential mechanisms in IL-6/PTTG1 modulated castration resistance
in CRPC.
2 | MATERIALS AND METHODS
2.1 | Cell culture
Human LNCaP, PC3 and DU145 prostate cancer cells were obtained
from the American Type Culture Collection (ATCC, Manassas, VA,
USA) and routinely tested to exclude mycoplasma contamination. All
cells were maintained in RPMI 1640 supplemented with 10% FBS
and 1% penicillin-streptomycin (both were purchased from Gibco-
Life Technologies, Grand Island, NY, USA). All cells were cultured at
37°C in 5% CO2 and 95% air.
The plasmid containing the wild-type full-length sequence of
PTTG1 and IL-6, and shRNA targeted to human PTTG1 were
produced by Genema (Shanghai, China). LNCaP and DU145 cells
were transfected with recombinant lentiviruses and screened by pur-
omycin. LNCaP cells expressing transgene PTTG1 or IL-6 were
named as LNCaP/PTTG1 or LNCaP/IL-6, and LNCaP cells trans-
fected with control recombinant lentiviruses were nominated as
LNCaP/Control. DU145 cells treated with negative control shRNA or
shRNA targeted to PTTG1 were named as DU145/ncPTTG1 or
DU145/shPTTG1, respectively.
2.2 | Clinical samples and immunohistochemical
staining
Five prostate tissue specimens from CRPC patients and 5 prostate
tissue specimens from patients with initial prostate cancer were
collected in the Department of Urology, Second Affiliated Hospital,
Third Military Medical University, China. After being fixed with
formalin, all samples were embedded in paraffin and serially cut
for IHC staining. The experiment was approved by the Institu-
tional Review Board of the Third Military Medical University,
China and was performed in accordance with the provisions of
the Declaration of Helsinki.15 As previously described,16 IHC stain-
ing was performed to investigate PTTG1 expression in the 5
paired prostate tissue specimens. Then, immunoreactive score (IRS)
was calculated to measure the protein expression levels of PTTG1,
as previous described.16 Briefly, the IRS, which ranged from 0 to
12, was composited by the sub-scores for the percentage of
immunoreactive cells (0-4) and immunoreactive intensity (0-3). The
percent positivity was scored as “0” (<1%), “1” (1%-10%), “2”
(11%-50%), “3” (51%-80%) and “4” (>80%). The staining intensity
was scored as “0” (negative), “1” (weak), “2” (moderate) and “3”
(strong). IRS was considered negative (0-1), weakly positive (2-4),
moderately positive (6-8) and strongly positive (9-12). The sections
were incubated with the PTTG1 primary antibody (dilution 1:200;
Abcam).
2.3 | Tumor xenografts
All animal studies were reviewed and approved by the Animal Care
and Use Committee of the Second Affiliated Hospital and Third Mili-
tary Medical University. Four-week-old male athymic nude mice
were purchased from the Experimental Animals Center of the Third
Military Medical University (Chongqing, China). Nude mice were sur-
gically castrated 1 week prior to subcutaneous injection with
5 9 106 LNCaP/Control and LNCaP/PTTG1 cells mixed with Matri-
gel (1:1 [vol/vol]) (n = 15 in each group), or with 2 9 106 DU145/
ncPTTG1 and DU145/shPTTG1 cells (n = 15 in each group). After
injection, all nude mice also received intraperitoneal injections of
bicalutamide (50 mg/kg body weight, 3 times/wk). Tumor volume
was calculated every 2 weeks according to the following formula:
TV = (Length) 9 (Width)2/2. The subcutaneous tumor-bearing mice
were killed at the 6th week after implantation and then tumor
weights were measured.
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2.4 | Flow cytometric analysis
Following the established protocol,17 LNCaP cells were trypsinized
and washed once with FACs buffer (PBS containing 1.5% BSA and
5 mM EDTA). 106 cells were incubated with 10 lL primary antibod-
ies: anti-CD24-FITC and anti-CD44-PE (both were purchased from
Abcam) in 100 lL buffer at 4°C for 15 minutes. Following incuba-
tion, cells were washed once with FACs buffer. For flow cytometric
sorting, cells were resuspended in FACs buffer at 2 9 107 cells/mL
and separated on either an Aria cell sorter (BD Biosciences, San
Jose, CA, USA) or a MoFlo High Performance cell sorter (Dako
Cytomation, Carpinteria, CA, USA).
2.5 | Luciferase assays
For luciferase assays, PTTG1 promoters, 2000/+1, 1500/+1,
1000/+1 and 500/+1 were cloned into Pmir-GLO-P luciferase
reporter vector (Promega, Madison, WI, USA), and were named as
Pmir/2000, Pmir/1500, Pmir/1000 and Pmir/500. The follow-
ing primers were used: forward 50-GAAGATCTACCTCAAAACCTCT
GTAGATAGA-30 , 50-GAAGATCTATATGGAATCAACTCCTCTCTCT
C-30, 50-GAAGATCTAAGTATTGAGGATAGTCCTAAG-30, 50-CCGCTC
GAGGCGGCGCACTCCTGGTTTAA-30 and reverse 50-GCGGCGCACT
CCTGGTTTAA-30. The primers used for generating site mutated pro-
moter plasmid were: forward 50-ACGTAAAAAACTAGGATCGTGTA
AT-30 and reverse 50-TTTTTACGTGCCACAAAGTTTGCAAG-30
(deleting the cis-regulatory element in plasmid Pmir/500). The
mutated plasmid was named Pmir/M500.
Transfections were done using Lipofectamine 2000 Transfection
reagents (Invitrogen) according to the manufacturer’s instructions.
Cells were planted into 24-well plates, and were transfected with
0.5 lg PTTG1 promoter-Pmir-GLO-P at 70%-80% confluence. After
24 hours, whole-cell lysate was collected for reporter detection by
the Dual Luciferase Reporter System (Promega). Reactions were
measured using an Orion Microplate Luminometer (Berthold Detec-
tion System, Tanja Vicentic, Germany). Transfections were performed
in triplicate and repeated 3 times to assure reproducibility.
2.6 | Statistical analysis
Data are presented as the mean  SD. All experiments were per-
formed with at least 3 independent replications. Statistical analyses
were conducted using SPSS 13.0 software (SPSS, Chicago, IL, USA),
and significant difference between each group was analyzed using
unpaired 2-tailed Student’s t tests or one-way ANOVA. Differences
were considered to be statistically significant at P < .05.
2.7 | Supplemental experimental procedures
Data S1 contains a detailed description of the western blot analysis,
quantitative RT-PCR, in vitro growth assays, clonogenic assays,
tumor sphere formation assays and ChIP assays.
F IGURE 1 Pituitary tumor transforming
gene1 (PTTG1) expression in prostate
cancer cells and specimens. A-C, PTTG1
protein and mRNA expressions were
higher in PC3 and DU145 cells than that
in LNCaP cells. D,E, Immunohistochemical
analysis demonstrated that PTTG1
expression was increased in castration-
resistant prostate cancer (CRPC) patients
compared with initial prostate cancer (PCa)
patients. (Data are presented as
mean  SD, *P < .05.)
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3 | RESULTS
3.1 | Pituitary tumor transforming gene 1
expression was increased in castration-resistant
prostate cancer specimens and androgen-deprivation
therapy-resistant prostate cancer cells
We detected that PTTG1 mRNA and protein expression levels were
significantly increased in PC3 and DU145 cells compared with that
in LNCaP cells (Figure 1A-C). Furthermore, using IHC staining, we
examined the PTTG1 expression in 5 paired prostate tissue speci-
mens from patients with CRPC or initial prostate cancer (initial PCa),
whose details were listed in Table 1. There were no significant dif-
ferences of age and Gleason score between patients with CRPC and
initial PCa. Average time for ADT in patients with CRPC were
56.0  23.6 months. Subsequently, we found that PTTG1 expres-
sion in prostate cancer tissues from CRPC patients was higher than
that in prostate cancer tissues from initial PCa patients (Figure 1D,
E).
3.2 | Pituitary tumor transforming gene 1
overexpression in LNCaP cells promoted the
resistance to androgen-deprivation therapy in vitro
and in vivo
To investigate the role of PTTG1 in CRPC development, we first uti-
lized recombinant lentiviruses transfection to reach PTTG1 overex-
pression in LNCaP cells. Successfully, we found that PTTG1 protein
and mRNA expressions were overexpressed in LNCaP/PTTG1 cells
compared with LNCaP/Control cells (Figure 2A-C). As shown in Fig-
ure 2D, upon the increasing doses of bicalutamide (1-5 lM) treat-
ments, LNCaP/Control cells showed higher sensitivity to
bicalutamide treatment than LNCaP/PTTG1 cells. 1 lM bicalutamide
reduced the cell survival rate of LNCaP/Control cells by more than
45%, while it had little effect on the cell survival rate of LNCaP/
PTTG1 cells. Even at a higher concentration of bicalutamide (5 lM),
the cell survival rate reduction in LNCaP/PTTG1 cells was only
approximately 30% compared with almost 65% reduction in LNCaP/
Control cells.
TABLE 1 Details of clinical prostate cancer specimens
Pca type Age (y) Gleason score Time for ADT (mo)
Initial Pca 70.8  10.0 7.0  1.0 0
CRPC 79.8  2.6 8.2  0.8 56.0  23.6
ADT, androgen-deprivation therapy; CRPC, castration-resistant prostate
cancer; PCa prostate cancer.
F IGURE 2 Pituitary tumor transforming gene1 (PTTG1) overexpression in LNCaP cells led to resistant androgen deprivation. A-C, PTTG1
protein and mRNA expressions were overexpressed in LNCaP/PTTG1 cells compared with LNCaP/Control cells (Data are presented as
mean  SD, *P < .05 and ***P < .001). D, Upon the different doses of bicalutamide (1-5 lM) treatments in medium containing complete FBS
for 48 h, the cell survival rate in LNCaP/PTTG1 cells was significantly higher than that in LNCaP/Control cells (Data are presented as
mean  SD, **P < .01). E,F, Results in clonogenic assays demonstrated that LNCaP/PTTG1 cells formed higher numbers of colonies when
treated with 5 lM bicalutamide and charcoal stripped FBS (CS-FBS) compared with LNCaP/Control cells (Data are presented as mean  SD,
**P < .01). G, In castrated male nude mice treated with bicalutamide, LNCaP/PTTG1 cells exhibited stronger tumorigenicity than LNCaP/
Control cells. H, Tumors were harvested at the 6th week, and tumor weights in LNCaP/PTTG1 group were significantly greater than that in
LNCaP/Control group. (Data are presented as mean  SD, *P < .05.) I, After cell injection, tumor volumes were measured every 2 weeks.
Tumor volumes in LNCaP/PTTG1 group were significantly bigger than that in LNCaP/Control group at the 4th and 6th week. (Data are
presented as mean  SD, *P < .05.)
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To further test the influence of PTTG1 overexpression on the
LNCaP cells clonality upon the treatment with 5 lM bicalutamide or
charcoal stripped FBS (CS-FBS), clonogenic assays in vitro were per-
formed. We found that compared with LNCaP/Control cells, LNCaP/
PTTG1 cells formed higher numbers of colonies when treated with
5 lM bicalutamide or CS-FBS (Figure 2E,F). Consistent with the
in vitro studies, PTTG1 overexpression resulted in stronger tumori-
genicity in the xenograft model. In castrated male nude mice treated
with bicalutamide, LNCaP/PTTG1 cells exhibited higher tumor for-
mation rate than LNCaP/Control cells (6/15 in LNCaP/PTTG1 vs 3/
15 in LNCaP/Control) (Figure 2G). Tumor weight and volume in
LNCaP/PTTG1 group were also significantly greater than that in
LNCaP/Control group (Figure 2H,I).
3.3 | Knockdown of pituitary tumor transforming
gene 1 expression enhanced the sensitivity of DU145
cells to androgen-deprivation therapy in vitro and
in vivo
We further knocked down PTTG1 expression in DU145 cells to ver-
ify the functional role of PTTG1 in CRPC development. Three
shRNA targeted to human PTTG1 were used. Compared with the
negative control shRNA (ncPTTG1), all the 3 shRNA significantly
reduced the PTTG1 mRNA expression in DU145 cells, and such
reduction induced by the 3rd shRNA (shPTTG1-3) was the most sig-
nificant (Figure 3A). Western blot analysis demonstrated that
shPTTG1-3 also significantly decreased the PTTG1 protein expres-
sion in DU145 cells compared with ncPTTG1 (Figure 3B,C). After-
wards, we detected that the increasing doses of bicalutamide (1-
5 lM) had no significant effects on DU145/ncPTTG1 cells, but bica-
lutamide in concentration of 2.5 and 5 lM significantly decreased
the cell survival rate of DU145/shPTTG1-3 cells (Figure 3D). Fur-
thermore, using clonogenic assays, we found that DU145/ncPTTG1
cells formed more colonies than DU145/shPTTG1-3 cells upon the
treatment with 5 lM bicalutamide or CS-FBS (Figure 3E,F).
Contrary to PTTG1 overexpression, PTTG1 expression knock-
down led to weaker tumorigenicity in the castrated male nude
mice treated with bicalutamide. Results showed that tumor forma-
tion rate of DU145/shPTTG1-3 cells was significantly lower than
that of DU145/ncPTTG1 cells (8/15 in DU145/shPTTG1-3 vs 12/
15 in DU145/ncPTTG1) (Figure 3G). Tumor weight and volume in
DU145/ncPTTG1 group were also significantly greater than that in
DU145/shPTTG1-3 group (Figure 3H,I). These results in gain-of-
function and loss-of-function studies of PTTG1 indicated the
functional importance of PTTG1 in the development of ADT
resistance.
F IGURE 3 Knockdown of pituitary tumor transforming gene1 (PTTG1) expression restored the sensitivity of DU145 cells to ADT. A, Three
shRNA targeted to human PTTG1 were utilized to knock down PTTG1 expression. Compared with the negative control shRNA (ncPTTG1), all
the 3 shRNA significantly decreased the PTTG1 mRNA expression in DU145 cells, and the decrease induced by the 3rd shRNA (shPTTG1-3)
was the most significant. (Data are presented as mean  SD, ***P < .001.) B,C, shPTTG1-3 also significantly reduced the PTTG1 protein
expression in DU145 cells compared with ncPTTG1 (Data are presented as mean  SD, ***P < .001.) D, DU145/ncPTTG1 cells showed
obvious resistance to bicalutamide (1-5 lM) treatment, while shPTTG1-3 significantly restored the sensitivity of DU145 cells to bicalutamide
(2.5 and 5 lM) treatment. (Data are presented as mean  SD, **P < .01 and ***P < .001.) E,F, Furthermore, results in clonogenic assays
demonstrated that the numbers of DU145/ncPTTG1 cells formed colony were significantly higher than that of DU145/shPTTG1-3 cells upon
the treatment with 5 lM bicalutamide or CS-FBS. (Data are presented as mean  SD, **P < .01.) G, DU145/shPTTG1-3 cells manifested
weaker tumorigenicity than DU145/ncPTTG1 cells in castrated male nude mice treated with bicalutamide. H, At the 6th week, the tumor
weights in DU145/shPTTG1-3 group were significantly lighter than that in DU145/ncPTTG1 group. (Data are presented as mean  SD,
*P < .05.) I, Tumor volumes in DU145/shPTTG1-3 group were also significantly smaller than those in the DU145/ncPTTG1 group at the 4th
and 6th week. (Data are presented as mean  SD, **P < .01.)
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3.4 | Pituitary tumor transforming gene 1
overexpression induced prostate cancer epithelial-
mesenchymal transition and regulated the prostate
cancer stem cell population
To explore exact role of PTTG1 in affecting ADT resistance, we first
detected the effect of PTTG1 overexpression on epithelial-mesench-
ymal transition (EMT). Western blot analysis showed that PTTG1
overexpression upregulated the expressions of N-cadherin, Vimentin,
Snail and downregulated the E-cadherin expression (Figure 4A,B).
Because of EMT is accompanied by the gain of stem cell traits in
cancer cell populations,18 we next explored whether the stem cell
properties of LNCaP cells were changed by PTTG1 overexpression.
Firstly, we found that the protein expressions of cancer stem cell
biomarkers, Sox2 and Nanog, were significantly increased by PTTG1
overexpression (Figure 4A,B). Then, we used tumor sphere formation
assays to test the changes in sphere-forming ability of LNCaP cells
induced by PTTG1 overexpression. Notably, the sphere numbers in
LNCaP/PTTG1 group were significantly increased compared with
that in LNCaP/Control group (Figure 4C,D). This result suggested
that PTTG1 may be required for self-renewal of prostate cancer
stem cells. Moreover, a previous study reported that prostate cancer
stem cells are enriched in CD44+/CD24 cell population.17 Subse-
quently, using FACS analysis, we detected that PTTG1 overexpres-
sion caused an increase in the CD44+/CD24- cell population in
LNCaP cells (Figure 4E,F). Taken together, these data suggested that
PTTG1 plays a pivotal role in maintaining prostate cancer stem cell
populations.
3.5 | Interleukin-6 increased pituitary tumor
transforming gene 1 expression via activating signal
transducer and activator of transcription 3 in LNCaP
cells
Furthermore, we attempted to verify whether PTTG1 is regulated
by IL-6 in prostate cancer and to clarify the potential mechanism.
F IGURE 4 Pituitary tumor transforming gene1 (PTTG1) overexpression induced prostate cancer epithelial-mesenchymal transition (EMT)
and regulated the prostate cancer stem cell population. A,B, Western blotting demonstrated that PTTG1 overexpression resulted in down-
expression of E-cadherin and up-expression of N-cadherin, vimentin, snail, Sox2 and Nanog, which were biomarkers of EMT and stem cells.
(Data are presented as mean  SD, *P < .05 and **P < .01.) C,D, Sphere formation assays were performed in LNCaP/PTTG1 and LNCaP/
Control cells. LNCaP/PTTG1 cells formed greater sphere numbers than LNCaP/Control cells (Data are presented as mean  SD, **P < .01.) E,
F, Using fluorescence activated cell sorting (FACS), prostate cancer stem cell population was quantified. CD44+/CD24 cell number in LNCaP/
PTTG1 group was significantly increased compared with that in the LNCaP/Control group (Data are presented as mean  SD, *P < .05.)
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We first expressed IL-6 in LNCaP cells which possess negative IL-6
expression by lentiviral transfection (Figure 5A-C). IL-6 expression
significantly increased the protein and mRNA expressions of
PTTG1, which can be significantly attenuated by AG490 (a STAT3
blocker, 20 lM) (Figure 5A,B,D). These results suggested that IL-6
may regulate PTTG1 expression via activating STAT3 in LNCaP
cells.
In addition, to clarify the potential regulatory mechanism, we first
analyzed regulatory regions of PTTG1 gene using a web-based tool
(Consite) for finding cis-regulatory elements of STAT3 in genomic
sequences. We found some putative cis-regulatory elements of
STAT3 binding site in the PTTG1 promoter region (Figure 5E). Then,
plasmids Pmir/2000, Pmir/1500, Pmir/1000 and Pmir/500
were transfected into LNCaP cells in order to measure their tran-
scriptional activities responding to IL-6 expression. Luciferase assays
demonstrated that all PTTG1 promoter fragments including 2000/
+1, 1500/+1, 1000/+1 and 500/+1 exhibited strong luciferase
activities responding to IL-6 expression (Figure 5F). These data
indicated that the STAT3 response element localized in the region of
500 to +1. Moreover, one putative STAT3 binding site in the pro-
moter region of 500 to +1 was postulated using web-based tools.
To further confirm the responsibility of this putative STAT3 binding
site for IL-6 stimulated transcription, this cis-regulatory element was
deleted by a special primer. As expected, the mutated promoter con-
struct did not respond to IL-6 expression (Figure 5G). To further
confirm that STAT3 mediates androgen-induced PTTG1 transcription
in vivo, we immunoprecipitated cross-linked chromatin from LNCaP
cells with a STAT3 primary antibody. By amplifying region of 500
to +1 in PTTG1 promoter which around STAT3 binding site
sequence, the precipitated chromatin was analyzed. As shown in Fig-
ure 5H, the putative STAT3 binding site sequence of PTTG1 were
immunoprecipitated by the anti-STAT3 antibody in extracts from
LNCaP/IL-6 cells, indicating that endogenous STAT3 protein can
bind to the PTTG1 promoter in the presence of IL-6 in LNCaP cells.
These results suggested that PTTG1 expression can be regulated by
IL-6 via the directly binding of activated STAT3 to PTTG1 promoter.
F IGURE 5 Interleukin-6 (IL-6) increased pituitary tumor transforming gene 1 (PTTG1) expression via activating signal transducer and
activator of transcription 3 (STAT3) in LNCaP cells. A-D, IL-6 was expressed in LNCaP cells with lentiviral transfection. After IL-6 expression,
PTTG1 protein and mRNA expressions were significantly increased in LNCaP/IL-6 cells. 20 lM AG490 significantly weakened the effect of IL-
6 on PTTG1 expression. (Data are presented as mean  SD, *P < .05, **P < .01 and ***P < .001.) E, Schematic representation of potential
STAT3 binding sites on PTTG1 promoter. F,G, Using luciferase reporter assays, the transcriptional activities of different PTTG1 promoter
deletion constructs were quantified in LNCaP/Control and LNCaP/IL-6 cells. (Data are presented as mean  SD, ***P < .001.) H, Putative
STAT3 binding site sequence of PTTG1 were immunoprecipitated by an anti-STAT3 antibody in extracts from LNCaP/IL-6 cells. No signal was
detected in the control IgG lane while control PCR reactions show robust amplification of the target sequence in input DNA
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3.6 | Signal transducer and activator of
transcription 3 inhibition significantly resensitized the
DU145 cells to bicalutamide treatment
Subsequently, we tried to explore whether STAT3 inhibition can
resensitize the androgen-independent cells to ADT. AG490 (20 lM)
was used to block STAT3 in DU145 cells. We confirmed that
DU145 cells were resistant to 5 lM bicalutamide treatment. How-
ever, the combined application with bicalutamide and AG490 signifi-
cantly reduced the colony numbers of DU145 cells compared with
that of DU145 cells treated with single bicalutamide or AG490 (Fig-
ure 6A,B). Consistently, we detected that DU145 cells received the
combined application with bicalutamide and AG490 possessed lower
cell survival rate than that treated with single bicalutamide or
AG490 (Figure 6C).
4 | DISCUSSION
In the present study, we found that PTTG1 expression was signifi-
cantly increased in androgen-independent prostate cancer cell lines
PC3 or DU145 and CRPC specimens. PTTG1 overexpression in
LNCaP cells and PTTG1 expression knockdown in DU145 cells sig-
nificantly promoted and attenuated the resistance to ADT, respec-
tively. Subsequently, we found that PTTG1 overexpression can
induce EMT and increase cancer stem cell population in LNCaP cells.
Furthermore, we demonstrated that PTTG1 expression can be regu-
lated by IL-6 via the directly binding of activated STAT3 to PTTG1
promoter in LNCaP cells. Moreover, STAT3 inhibition significantly
resensitized the androgen-independent DU145 cells to bicalutamide
treatment. Taken together, these results indicate that PTTG1 can be
regulated by IL-6/STAT3 and participate in the development and
progression of CRPC via inducing prostate cancer EMT and increas-
ing the cancer stem cell population.
In breast cancer, PTTG1 expression in specimens from ER-posi-
tive breast cancer patients who recurred after tamoxifen treatment
is found to be significantly increased compared with specimens from
patients who did not.19 Moreover, in prostate cancer, PTTG1 over-
expression is an unfavorable prognostic factor for progression in
advanced prostate cancer receiving hormone therapy.20 In the pre-
sent study, we also found that PTTG1 expression in specimens from
CRPC patients was significantly higher than that in specimens from
initial PCa patients. Moreover, we reconfirmed the androgen-inde-
pendent prostate cancer cell lines PC3 and DU145 possess greater
PTTG1 expression than androgen-dependent prostate cancer cell line
LNCaP. Based on these results, we speculate that PTTG1 may play a
vital role in the development and progression of endocrine therapy
resistance. Moreover, the subsequent gain-of-function and loss-of-
function experiments of PTTG1 further confirmed the functional
importance of PTTG1 in the development of ADT resistance.
Many mechanisms have been proposed to explain the CRPC
development: hypersensitive pathways, promiscuous receptor, coac-
tivators and corepressors, bypass pathway and prostate cancer stem
cells.13 In recent years, a substantial body of evidence suggests that
cancer stem cells (CSC) play an important role in the development of
CRPC. CSC possess many phenotypic and functional properties asso-
ciated with normal stem cells and is proposed to be responsible for
tumor initiation, progression including castration resistance and
metastasis.21 It has been reported that the occurrence and develop-
ment of CRPC are ascribed to clonal expansion of a small percentage
of androgen-independent cells, which are considered to be the
androgen-independent epithelial stem cells.22 In addition, therapy
strategy by combining wnt inhibitor with docetaxel to target CSC
can significantly enhance the therapeutic efficacy of CRPC.23
F IGURE 6 Signal transducer and activator of transcription 3 (STAT3) inhibitor, AG490, reversed bicalutamide resistance in DU145 cells.
DU145 cells were treated with 5 lM bicalutamide combined with or without 20 lM AG490, clonogenic assays were performed and cell
survival rate was calculated. As expected, we confirmed that DU145 cells were resistant to 5 lM bicalutamide treatment. However, the
combined application with bicalutamide and AG490 significantly reduced the colony numbers (A and B) and cell survival rate (C) of DU145
cells compared with that of DU145 cells treated with single bicalutamide or AG490. (Data are presented as mean  SD, **P < .01 and
***P < .001.)
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Moreover, Piyush et al24 have successfully identified agents with
specific toxicity for epithelial CSC using high-throughput chemical
screening. In the current study, we demonstrated that PTTG1 over-
expression significantly enhanced the sphere-forming ability and
increased CSC population in LNCaP cells. Also, the expressions of
Sox2 and Nanog which can regulate the gain of CSC phenotypes
and properties in tumor cells22 were significantly increased due to
PTTG1 overexpression. These data suggest that PTTG1 can affect
the development of CRPC via improving CSC stemness. To our
knowledge, EMT also plays a pivotal role in the development of
CRPC.22 EMT is a developmental process that epithelial-derived
tumor cells reduced intercellular adhesion and acquired a migratory
and invasive mesenchymal phenotype.25,26 Therefore, it has been
proved that induction of an EMT in human mammary epithelial cells
results in the acquisition of epithelial stem-cell properties.18 In our
present study, we detected that after PTTG1 overexpression, the
expression of E-cadherin (epithelial marker) was downregulated and
the expressions of N-cadherin, Vimentin (mesenchymal markers) and
Snail (transcriptional repressors of E-cadherin) were upregulated,
which demonstrated the induction of EMT. In a previous study, it
had been shown that PTTG1 can induce EMT and promote expan-
sion of cancer stem cell population in breast cancer.27 Taken
together, we suggest that PTTG1 can regulate the CSC stemness via
inducing EMT, and facilitate the development of CRPC.
Subsequently, we tried to clarify the potential regulatory mecha-
nism underlying the involvement of PTTG1 in CRPC. We focused on
a pleiotropic cytokine IL-6 due to its important role in the progres-
sion of CRPC.14 As we know, the effect of IL-6 on tumor cell prolif-
eration and metastasis is mediated by STAT3 activation.28,29 In our
study, we found that IL-6 increased PTTG1 expression via activating
STAT3 in LNCaP cells. This result is consistent with that IL-6 upreg-
ulates PTTG1 expression via activating STAT3 in colorectal cancer.30
Meanwhile, we detected that STAT3 binds to special cis-acting ele-
ment on the region 500 to +1 of PTTG1 promoter. However, in
colorectal cancer, STAT3 binding site is located on the region 2642
to 1717 of PTTG1 promoter.30 These results suggest that STAT3
can regulate PTTG1 expression by binding to different site of PTTG1
promoter in various cancers. Moreover, in accordance with a previ-
ous report by others that AG490 reversed the enzalutamide resis-
tance in LNCaP-s17 Cells which is resistant to ADT,31 we also found
that STAT3 inhibition by AG490 significantly resensitized the
DU145 cells to bicalutamide treatment. In addition, overexpression
of constitutively active STAT3 in LNCaP cells can induce resistance
to ADT and knockdown of STAT3 expression can restore the sensi-
tivity of LNCaP-s17 cells to enzalutamide treatment.31,32 These data
reveal the crucial role of STAT3 in development of ADT resistance.
Taken together, we speculate that IL-6/STAT3 may critically modu-
late the development of CRPC via regulating PTTG1 expression. Fur-
thermore, more recent studies have suggested that IL-6/STAT3
activation is involved in EMT induction and stem-cell properties
acquisition in many cancers,33-36 further proving that PTTG1 can be
regulated by IL-6/STAT3 and play its important role in CRPC via
inducing EMT and improving CSC stemness.
Although, our findings illustrate a causative link between PTTG1
and EMT, as well as the gain of stem-cell properties in prostate can-
cer cells, we can’t conclude that whether this link is ascribe to direct
protein interaction or indirect regulation by other factors. In breast
cancer, PTTG1 can induce EMT via PI3K/AKT signaling.27 In ovarian
epithelial cancer, such effects of PTTG1 are achieved by regulating
TGF-b.37 Therefore, more in-depth studies are required to uncover
the mechanism underlying the regulation of EMT and the gain of
stem-cell properties in prostate cancer cells by PTTG1.
In conclusion, our study has demonstrated that PTTG1 is overex-
pressed in androgen independent prostate cancer cell lines and
CRPC specimens. Furthermore, we found that, as a response gene of
IL-6/STAT3, PTTG1 can promote the resistance to ADT via inducing
EMT and improving prostate CSC stemness. These results suggest
that PTTG1 plays a vital role in CRPC and that PTTG1 can be
regarded as a novel therapeutic target for CRPC.
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